by Eclosion Team | Oct 28, 2017 | Uncategorized
Geneva, Switzerland, and Paris, France, October 28, 2017 – 11:00 CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO) and Servier announced today post hoc analyses of 6-month data from the CHANGE-MS Phase 2b study of GNbAC1 for the treatment of patients with...